Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2123 | 2003 |
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ... Jama 316 (2), 171-181, 2016 | 1776 | 2016 |
Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1508 | 2006 |
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1184 | 2008 |
Maraviroc for previously treated patients with R5 HIV-1 infection RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ... New England Journal of Medicine 359 (14), 1429-1441, 2008 | 927 | 2008 |
Raltegravir with optimized background therapy for resistant HIV-1 infection RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ... New England Journal of Medicine 359 (4), 339-354, 2008 | 908 | 2008 |
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia A Lazzarin, B Clotet, D Cooper, J Reynes, K Arastéh, M Nelson, ... New England Journal of Medicine 348 (22), 2186-2195, 2003 | 855 | 2003 |
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society–USA Panel MS Hirsch, F Brun-Vézinet, TD Richard, SM Hammer, VA Johnson, ... Jama 283 (18), 2417-2426, 2000 | 814 | 2000 |
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management MS Hirsch, B Conway, TD Richard, VA Johnson, F Brun-Vézinet, B Clotet, ... Jama 279 (24), 1984-1991, 1998 | 733 | 1998 |
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel MS Hirsch, F Brun-Vézinet, B Clotet, B Conway, DR Kuritzkes, ... Clinical Infectious Diseases 37 (1), 113-128, 2003 | 676 | 2003 |
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel MS Hirsch, HF Günthard, JM Schapiro, FB Vézinet, B Clotet, SM Hammer, ... Clinical Infectious Diseases 47 (2), 266-285, 2008 | 673 | 2008 |
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ... Nature medicine 16 (4), 460-465, 2010 | 660 | 2010 |
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b … B Clotet, J Feinberg, J van Lunzen, MA Khuong-Josses, A Antinori, ... The Lancet 383 (9936), 2222-2231, 2014 | 643 | 2014 |
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two … B Clotet, N Bellos, JM Molina, D Cooper, JC Goffard, A Lazzarin, ... The Lancet 369 (9568), 1169-1178, 2007 | 617 | 2007 |
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial A Lazzarin, T Campbell, B Clotet, M Johnson, C Katlama, A Moll, ... The Lancet 370 (9581), 39-48, 2007 | 613 | 2007 |
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ... New England Journal of Medicine 359 (4), 355-365, 2008 | 606 | 2008 |
Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 580 | 2008 |
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial DA Margolis, J Gonzalez-Garcia, HJ Stellbrink, JJ Eron, Y Yazdanpanah, ... The Lancet 390 (10101), 1499-1510, 2017 | 520 | 2017 |
Update of the drug resistance mutations in HIV-1: Fall 2006 VA Johnson, F Brun-Vézinet, B Clotet, DR Kuritzkes, D Pillay, ... Top HIV Med 14 (3), 125-130, 2006 | 503* | 2006 |
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 491 | 2021 |